Surgical Site Infections Ssi Market

DelveInsight’s ‘Surgical Site Infection (SSI) – Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the Surgical Site Infection (SSI), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Surgical Site Infection (SSI) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted SSI symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Surgical Site Infection (SSI) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Surgical Site Infection (SSI) Disease Understanding and Treatment Algorithm

Surgical Site Infection (SSI) Overview

Surgical Site Infections (SSI) are the most common nosocomial infection and frequently cause morbidity and mortality among inpatients of hospitals. The Centre for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC) defines SSI as postoperative infection occurring within 30 days of a surgical procedure (or within one year for permanent implants).


SSIs are classified as either incisional or organ/space, with incisional SSIs being further subclassified as superficial (involving only skin and subcutaneous tissue) versus deep (involving underlying soft tissue). Bacteria have mainly been associated with SSIs, and Staphylococcus aureus has been the most frequently reported causative agent.


Various factors contribute to the risk of SSI occurrence, and preventative measures require an integrative approach that focuses on pre-, intra- and post-operative care. Several patient characteristics have been shown to have a significant, independent association for SSI prediction. These include, but are not limited to, diabetes, cigarette smoking, obesity, and coincident remote site infections or colonization.


It has been estimated that most cases of SSIs are preventable and can be treated with antibiotics. The effective control of SSIs relies on a multitude of interventions that include surveillance, antimicrobial prophylaxis, infection control programs, and education. Although SSIs are preventable and rates of SSIs have reduced in contemporary surgical units, its absolute elimination seems challenging. With the limited development of new antibiotics and the perpetual emergence of antibiotic-resistant strains, alternative antimicrobial interventions are going to be increasingly important in the coming years.


Surgical Site Infection (SSI) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Surgical Site Infection (SSI) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Surgical Site Infection (SSI) market report gives a thorough understanding of SSI symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides SSI symptoms of treatment algorithms and treatment guidelines for SSI symptoms in the US, Europe, and Japan.

Surgical Site Infection (SSI) Epidemiology

The epidemiology division’s Surgical Site Infection symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Surgical Site Infection (SSI) epidemiology segmented as the Total Surgical Procedures, Number of Surgical Procedures by Type, Total Incident cases of Surgical Site Infections (SSI) and Incidence of Surgical Site Infections (SSI) by Type. The report includes the Incident scenario of SSI symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Surgical Site Infection (SSI) Epidemiology

The epidemiology segment also provides the Surgical Site Infection (SSI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM incident cases of Surgical Site Infection (SSI) were 1,275,912 in 2020.

Surgical Site Infection (SSI) Drug Chapters

The drug chapter segment of the Surgical Site Infection (SSI) report encloses the detailed analysis of SSI marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Surgical Site Infection (SSI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


The surgical Site Infection (SSI) Treatment drug market is based on antibiotics such as Vancomycin and Linezolid (Cardiothoracic/related leg SSI), and Tigecycline IV (Abdominal SSI). Due to their easy availability and reach, these drugs have a higher penetration rate in the market, thereby adding up to the total revenue generated.

Products detail in the report…


Surgical Site Infection (SSI) Emerging Drugs


XF-73 (Exeporfinium Chloride) is a synthetic dicationic porphyrin derivative with antibacterial activity for the patients at risk of postoperative staphylococcal infection. XF-73 by Destiny Pharma belongs to a new class of drugs known as XF drugs and has confirmed bactericidal activity with a novel mechanism of action that differs from that of any existing families of antimicrobial agents. The US FDA has granted the drug Fast Track Designation to prevent post-surgical staphylococcal infections such as Methicillin-resistant Staphylococcus aureus (MRSA).

Products detail in the report…

Surgical Site Infection (SSI) Market Outlook

The Surgical Site Infection (SSI) market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Surgical Site Infection (SSI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a thorough detail of Surgical Site Infection (SSI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Surgical Site Infection (SSI) market in 7MM is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the Surgical Site Infection (SSI) market in 7MM. The prophylactic market size of SSI in the seven major markets was USD 418.79 million in 2020, which is estimated to increase at a CAGR of 22.84% for the study period (2018–2030). Similarly, the treatment market size of SSI was USD 648.86 million in 2020, and the market is estimated to decline at a CAGR of −1.88%.


The United States Market Outlook

This section provides a total of Surgical Site Infection (SSI) market size and market size by therapies in the United States.


The United States accounts for the largest SSI market size than the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


In Nov 2020, PolyPid Ltd. announced that D-PLEX100 received Breakthrough Therapy Designation from the US Food and Drug Administration to prevent surgical site infections (SSIs) in patients undergoing elective colorectal surgery. D-PLEX100 has the potential to transform the prevention of SSIs radically. D-PLEX100 is being developed to manage bone and soft tissue SSIs in the cardiac and abdominal surgery segment.


The dynamics of both prophylactic and surgical site infection treatment market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2021–2030. There are presently three emerging therapies focused on treating or preventing surgical site infection in either cardio or abdominal surgeries.


EU-5 Countries: Market Outlook

The total Surgical Site Infection (SSI) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Prophylactic Therapy segment is XF-73 under development by Destiny Pharma with its antimicrobial “XF” drug platform. XF-73 was awarded QIDP status in October 2015.


Japan Market Outlook

The total Surgical Site Infection (SSI) market size and market size by therapies in Japan are also mentioned.

Surgical Site Infection (SSI) Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Surgical Site Infection (SSI) market uptake by drugs, patient uptake by therapies, and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Surgical Site Infection (SSI) Pipeline Development Activities

The report provides insights into different therapeutic candidates in the Phase II and Phase III stage. It also analyses Surgical Site Infection (SSI) key players involved in developing targeted therapeutics.


Major players include XF-73 (Destiny Pharma Plc) and D-PLEX100 (PolyPid Ltd.), etc., being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Surgical Site Infection (SSI) emerging therapies.

Reimbursement Scenario in Surgical Site Infection (SSI)

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Surgical Site Infection (SSI) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Surgical Site Infection (SSI) market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Surgical Site Infection (SSI) Market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Surgical Site Infection (SSI), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Surgical Site Infection (SSI) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Surgical Site Infection (SSI) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Surgical Site Infection (SSI) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Surgical Site Infection (SSI) market

Report Highlights

  • In the coming years, Surgical Site Infection (SSI) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Surgical Site Infection (SSI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for SSI. The launch of emerging therapies will significantly impact the Surgical Site Infection (SSI) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for SSI.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Surgical Site Infection (SSI) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Surgical Site Infection (SSI) Pipeline Analysis
  • Surgical Site Infection (SSI) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Surgical Site Infection (SSI) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Surgical Site Infection (SSI) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Surgical Site Infection (SSI) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Surgical Site Infection (SSI) Market share (%) distribution in 2018, and how it would look in 2030?
  • What would be the Surgical Site Infection (SSI) total market Size as well as market Size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Surgical Site Infection (SSI) market Size during the forecast period (2018–2030)?
  • At what CAGR, the Surgical Site Infection (SSI) market is expected to grow by 7MM during the forecast period (2018–2030)?
  • What would be the Surgical Site Infection (SSI) market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Surgical Site Infection (SSI) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Surgical Site Infection (SSI)?
  • What is the historical Surgical Site Infection (SSI) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, and the UK), and Japan?
  • What would be the forecasted patient pool of Surgical Site Infection (SSI) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, and the UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Surgical Site Infection (SSI)?
  • Out of all 7MM countries, which country would have the highest incident population of Surgical Site Infection (SSI) during the forecast period (2018–2030)?
  • At what CAGR the population is expected to grow by 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Surgical Site Infection (SSI)?
  • What are the current treatment guidelines for treating Surgical Site Infection (SSI) in the USA, Europe, and Japan?
  • What are the Surgical Site Infection (SSI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Surgical Site Infection (SSI)?
  • How many therapies are developed by each company for the treatment of Surgical Site Infection (SSI)?
  • How many emerging therapies are in the mid-stage and late-stage of development to treat Surgical Site Infection (SSI)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Surgical Site Infection (SSI) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Surgical Site Infection (SSI) and their status?
  • What are the key designations that have been granted for the emerging therapies for Surgical Site Infection (SSI)?
  • What are the global historical and forecasted market of Surgical Site Infection (SSI)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Surgical Site Infection (SSI) market
  • To understand the future market competition in the Surgical Site Infection (SSI) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Surgical Site Infection (SSI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Surgical Site Infection (SSI) market
  • To understand the future market competition in the Surgical Site Infection (SSI) market

1. Key Insights

2. Report Introduction

3. Surgical Site Infection Prophylactic Market Overview at a Glance

3.1. Prophylactic Market Share (%) Distribution of Surgical Site Infection in 2018

3.2. Prophylactic Market Share (%) Distribution of Surgical Site Infection in 2030

4. Surgical Site Infection Treatment Market Overview at a Glance

4.1. Treatment Market Share (%) Distribution of Surgical Site Infection in 2018

4.2. Treatment Market Share (%) Distribution of Surgical Site Infection in 2030

5. Executive Summary of Surgical Site Infection

6. Disease Background and Overview

6.1. Introduction

6.2. Types

6.3. Signs and Symptoms

6.4. Causes

6.5. Risk Factors

6.5.1. Assessing Patient Risks during the Preoperative Phase

6.5.2. Modifiable and Non-Modifiable Host Risk Factors

6.5.3. Extrinsic or External Risk Factors

6.6 Pathogenesis

6.7. Diagnosis

6.7.1. Diagnosis Based on Types

6.7.2. Diagnosis Based on Microbes

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Patient Population of Surgical Site Infection

7.3. The United States

7.3.1. Assumptions and Rationale

7.3.2. Total Surgical Procedures in the United States

7.3.3. Number of surgical procedures by types in the United States

7.3.4. Total Incident cases of Surgical Site Infections in the United States

7.3.5. Incidence of Surgical Site Infections by types in the United States

7.4. EU5

7.4.1. Assumtions and Rationale

7.4.2. Germany

7.4.2.1. Total Surgical Procedures in Germany

7.4.2.2. Number of surgical procedures by types in Germany

7.4.2.3. Total Incident cases of Surgical Site Infections in Germany

7.4.2.4. Incidence of Surgical Site Infections by types in Germany

7.4.3. France

7.4.3.1. Total Surgical Procedures of Surgical Site Infection in France

7.4.3.2. Number of surgical procedures by types in France

7.4.3.3. Total Incident cases of Surgical Site Infections in France

7.4.3.4. Incidence of Surgical Site Infections by types in France

7.4.4. Italy

7.4.4.1. Total Surgical Procedures in Italy

7.4.4.2. Number of surgical procedures by types in Italy

7.4.4.3. Total Incident cases of Surgical Site Infections in Italy

7.4.4.4. Incidence of Surgical Site Infections by types in Italy

7.4.5. Spain

7.4.5.1. Total Surgical Procedures in Spain

7.4.5.2. Number of surgical procedures by types in Spain

7.4.5.3. Total Incident cases of Surgical Site Infections in Spain

7.4.5.4. Incidence of Surgical Site Infections by types in Spain

7.4.6. United Kingdom

7.4.6.1. Total Surgical Procedures in the United Kingdom

7.4.6.2. Number of surgical procedures by types in the United Kingdom

7.4.6.3. Total Incident cases of Surgical Site Infections in the United Kingdom

7.4.6.4. Incidence of Surgical Site Infections by types in the United Kingdom

7.5. Japan

7.5.1. Assumptions and Rationale

7.5.2. Total Surgical Procedures in Japan

7.5.3. Number of surgical procedures by types in Japan

7.5.4. Total Incident cases of Surgical Site Infections in Japan

7.5.5. Incidence of Surgical Site Infections by types in Japan

8. Treatment and Management

8.1. Treatment Algorithm of Surgical Site Infections (SSIs)

9. Prevention

9.1. Preoperative Measures

9.2. Intraoperative Measures

9.3. Postoperative Measures

9.4. Antibiotic Prophylaxis (AP)

9.5. Prevention Guideline for Surgical Site Infections (SSIs)

9.5.1. Centers for Disease (CDC): Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017

9.5.2. World Health Organization (WHO): Global Guidelines for the Prevention of Surgical Site Infection

9.3.3. National Institute for Health and Care Excellence (NICE): Surgical Site Infections: Prevention and Treatment Guidelines

10. Organizations contributing towards Surgical Site Infection

11. Patient Journey

12. Case Report

13. Emerging Therapies

13.1. XF-73: Destiny Pharma

13.1.1. Drug Description

13.1.2. Regulatory Milestones

13.1.3. Clinical Development

13.1.4. Clinical Trials Information

13.1.5. Safety and Efficacy

13.1.6. Product Profile

13.2 D.-PLEX100: PolyPid

13.2.1. Drug Description

13.2.2. Regulatory Milestones

13.2.3. Clinical Development

13.2.4. Clinical Trials Information

13.2.5. Safety and Efficacy

13.2.6. Product Profile

13.3 Delafloxacin: Menarini Group Pharma

13.3.1. Drug Description

13.3.2. Regulatory Milestones

13.3.3. Clinical Development

13.3.4. Clinical Trials Information

13.3.5. Product Profile

13.4. BTX 1801: Botanix Pharma

13.4.1. Drug Description

13.4.2. Regulatory Milestones

13.4.3. Safety and Efficacy

13.4.4. Product Profile

13.5. DFA-02: Dr. Reddy’s Laboratories Ltd.

13.5.1. Drug Description

13.5.2. Regulatory Milestones

13.5.3. Clinical Development

13.5.4. Clinical Trials Information

13.5.5. Safety and Efficacy

13.5.6. Product Profile

13.6. Zuragard: Zurex Pharma

13.6.1. Drug Description

13.6.2. Clinical Development

13.6.3. Clinical Trials Information

13.6.4. Safety and Efficacy

13.6.5. Product Profile

14. Surgical Site Infection: Seven Major Market Analysis

14.1. Key Findings

14.2. Treatment Market Size of Surgical Site Infection in 7MM

14.3. Prophylactic Market Size of Surgical Site Infection in 7MM

14.4. Market Outlook

14.5. United States Market Size

14.5.1. Prophylaxis Market Size by Therapy

14.5.2. Surgical Site Infections - Treatment Market Size by Therapy

14.6. EU-5 Market Size

14.6.1. Germany

14.6.1.1. Prophylaxis Market Size by Therapy

14.6.1.2. Surgical Site Infections - Treatment Market Size by Therapy

14.6.2. France

14.6.2.1. Prophylaxis Market Size by Therapy

14.6.2.2. Surgical Site Infections - Treatment Market Size by Therapy

14.6.3. Italy

14.6.3.1. Prophylaxis Market Size by Therapy

14.6.3.2. Surgical Site Infections - Treatment Market Size by Therapy

14.6.4 Spain

14.6.4.1. Prophylaxis Market Size by Therapy

14.6.4.2. Surgical Site Infections - Treatment Market Size by Therapy

14.6.5. United Kingdom

14.6.5.1. Prophylaxis Market Size by Therapy

14.6.5.2. Surgical Site Infections - Treatment Market Size by Therapy

14.7. Japan

14.7.1. Prophylaxis Market Size by Therapy

14.7.2. Surgical Site Infections - Treatment Market Size by Therapy

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight 

List of Table

Table 1: Summary of Surgical Site Infection, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Summary of treatment market size of SSI (2018–2030)

Table 3: Types of Surgical Site Infections (SSIs)

Table 4: Pathogens commonly associated with Different Surgical Procedures

Table 5: Host (Intrinsic or Internal) Characteristics in Surgical Patients

Table 6: Types of Surgical Site Infections (SSIs)

Table 7: Total Patient Population of Surgical Site Infection in thousands in 7MM (2018–2030)

Table 8: Total Surgical Procedures in the United States (2018–2030)

Table 9: Number of surgical procedures by types in thousands in the United States (2018–2030)

Table 10: Total Incidence cases of Surgical Site Infections in the United States (2018–2030)

Table 11: Incidence of Surgical Site Infection by types in the United States (2018–2030)

Table 12: Total Surgical Procedures in thousands in Germany (2018–2030)

Table 13: Number of surgical procedures by types in Germany (2018–2030)

Table 14: Total Incidence cases of Surgical Site Infections in Germany (2018–2030)

Table 15: Incidence of Surgical Site Infection by types in Germany (2018–2030)

Table 16: Total Surgical Procedures in thousands in France (2018–2030)

Table 17: Number of surgical procedures by types in thousands in France (2018–2030)

Table 18: Total Incident cases of Surgical Site Infections in France (2018–2030)

Table 19: Incidence of Surgical Site Infections by types in France (2018–2030)

Table 20: Total Surgical Procedures in thousands in Italy (2018–2030)

Table 21: Number of surgical procedures by types in thousands in Italy (2018–2030)

Table 22: Total Incident cases of Surgical Site Infections in Italy (2018–2030)

Table 23: Incidence of Surgical Site Infection by types in Italy (2018–2030)

Table 24: Total Surgical Procedures in thousands in Spain (2018–2030)

Table 25: Number of surgical procedures by types in thousands in Spain (2018–2030)

Table 26: Total Incident cases of Surgical Site Infections in Spain (2018–2030)

Table 27: Incidence of Surgical Site Infections by types in Spain (2018–2030)

Table 28: Total Surgical Procedures in thousands in the United Kingdom (2018–2030)

Table 29: Number of surgical procedures by types in thousands in the United Kingdom (2018–2030)

Table 30: Total Incident cases of Surgical Site Infections in the United Kingdom (2018–2030)

Table 31: Incidence of Surgical Site Infections by types in the United Kingdom (2018–2030)

Table 32: Total Surgical Procedures in thousands in Japan (2018–2030)

Table 33: Number of surgical procedures by types in thousands in Japan (2018–2030)

Table 34: Total Incident cases of Surgical Site Infections in Japan (2018–2030)

Table 35: Incidence of Surgical Site Infections by types in Japan (2018–2030)

Table 36: Surgical Site Infection (SSI) Treatment Algorithm

Table 37: Most Commonly Prescribed Agents for Patients Who Received Any Antimicrobial or Combination of Antimicrobials Consistent with Surgical Antimicrobial Prophylaxis Guidelines*

Table 38: Summary of core topics, research questions, and recommendations for the prevention of surgical site infection.

Table 39: Options for Antiseptic Skin Preparation

Table 40: XF-73, Clinical Trial Description, 2021

Table 41: D-PLEX100, Clinical Trial Description, 2021

Table 42: Delafloxacin, Clinical Trial Description, 2021

List of Figures

Figure 1: Total Patient Population of Surgical Site Infection in thousands in 7MM (2018–2030)

Figure 2: Total Surgical Procedures in thousands in the United States (2018–2030)

Figure 3: Number of surgical procedures by types in thousands in the United States (2018–2030)

Figure 4: Total Incident cases of Surgical Site Infections in the United States (2018–2030)

Figure 5: Incidence of Surgical Site Infection by types in the United States (2018–2030)

Figure 6: Total Surgical Procedures in thousands in Germany (2018–2030)

Figure 7: Number of surgical procedures by types in thousands in Germany (2018–2030)

Figure 8: Total Incident cases of Surgical Site Infections in Germany (2018–2030)

Figure 9: Incidence of Surgical Site Infection by types in Germany (2018–2030)

Figure 10: Total Surgical Procedures in thousands in France (2018–2030)

Figure 11: Number of surgical procedures by types in thousands in France (2018–2030)

Figure 12: Total Incident cases of Surgical Site Infections in France (2018–2030)

Figure 13: Incidence of Surgical Site Infections by types in France (2018–2030)

Figure 14: Total Surgical Procedures in thousands in Italy (2018–2030)

Figure 15: Number of surgical procedures by types in thousands in Italy (2018–2030)

Figure 16: Total Incident cases of Surgical Site Infections in Italy (2018–2030)

Figure 17: Incidence of Surgical Site Infections by types in Italy (2018–2030)

Figure 18: Total Surgical Procedures in thousands in Spain (2018–2030)

Figure 19: Number of surgical procedures by types in thousands in Spain (2018–2030)

Figure 20: Total Incident cases of Surgical Site Infections in Spain (2018–2030)

Figure 21: Incidence of Surgical Site Infections by types in Spain (2018–2030)

Figure 22: Total Surgical Procedures in thousands in the United Kingdom (2018–2030)

Figure 23: Number of surgical procedures by types in thousands in the United Kingdom (2018–2030)

Figure 24: Total Incident cases of Surgical Site Infections in the United Kingdom (2018–2030)

Figure 25: Incidence of Surgical Site Infections by types in the United Kingdom (2018–2030)

Figure 26: Total Surgical Procedures in thousands in Japan (2018–2030)

Figure 27: Number of surgical procedures by types in thousands in Japan (2018–2030)

Figure 28: Total Incident cases of Surgical Site Infections in Japan (2018–2030)

Figure 29: Incidence of Surgical Site Infections by types in Japan (2018–2030)

Figure 30: Organizations contributing towards SSI

Figure 31: Treatment Market Size of Surgical Site Infection in 7MM in USD Million (2018–2030)

Figure 32: Prophylactic Market Size of Surgical Site Infection in USD Million (2018–2030)

Figure 33: Prophylaxis Market Size by Therapy in the United States, USD Million (2018–2030)

Figure 34: Market Size of Surgical Site Infection in the United States, USD Million (2018–2030)

Figure 35: Prophylaxis Market Size by Therapy in Germany, USD Million (2018–2030)

Figure 36: Market Size of Surgical Site Infection in Germany, USD Million (2018–2030)

Figure 37: Prophylaxis Market Size by Therapy in France, USD Million (2018–2030)

Figure 38: Market Size of Surgical Site Infection in France, USD Million (2018–2030)

Figure 39: Prophylaxis Market Size by Therapy in Italy, USD Million (2018–2030)

Figure 40: Market Size of Surgical Site Infection in Italy, USD Million (2018–2030)

Figure 41: Prophylaxis Market Size by Therapy in Spain, USD Million (2018–2030)

Figure 42: Market Size of Surgical Site Infection in Spain, USD Million (2018–2030)

Figure 43: Prophylaxis Market Size by Therapy in the United Kingdom, USD Million (2018–2030)

Figure 44: Market Size of Surgical Site Infection in the United Kingdom, USD Million (2018–2030)

Figure 45: Prophylaxis Market Size by Therapy in Japan, USD Million (2018–2030)

Figure 46: Market Size of Surgical Site Infection in Japan, USD Million (2018–2030)

Destiny Pharma

PolyPid

Menarini Group Pharma

Botanix Pharma

Dr. Reddy’s Laboratories Ltd.

Zurex Pharma

  • Tags:
  • Surgical Site Infections (SSI) mark...
  • Surgical Site Infections (SSI) mar...
  • Surgical Site Infections (SSI) mar...
  • Surgical Site Infections (SSI) mar...
  • Surgical Site Infections (SSI) mar...
  • Surgical Site Infections (SSI) mar...
  • Surgical Site Infections (SSI) pip...
  • Surgical Site Infections (SSI) tre...
  • Surgical Site Infections (SSI) dru...
  • Surgical Site Infections (SSI) sal...
  • Surgical Site Infections (SSI) mar...
  • Surgical Site Infections (SSI) dis...
  • Surgical Site Infections (SSI) epi...
  • Surgical Site Infections (SSI)

Forward to Friend

Need A Quote